MBX Biosciences, Inc.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. MBX Biosciences is advancing investigational programs built around its proprietary peptide platform to address conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Its pipeline includes canvuparatide, a parathyroid hormone replacement candidate, as well as additional peptide-based assets in clinical and preclinical development. The company’s work centers on designing long-acting therapies intended to improve treatment convenience and expand options in specialty endocrine care. Based in Carmel, Indiana, MBX Biosciences operates in the biotechnology and specialty therapeutics market, where it contributes to the development of targeted medicines for diseases with significant unmet medical needs.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Steven L. Hoerter

Employees

63

Headquarters

Carmel, IN, United States

Website

mbxbio.com